|
|
Drugs for Acute Basophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 108)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Lenograstim | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 1202 | 135968-09-1 | | G-CSF (CHO cell derived) Glycosylated recombinant G-CSF Glycosylated recombinant granulocyte colony stimulating factor | Granulocyte colony stimulating factor 3 (CHO cell derived) Granulocyte colony-stimulating factor lenograstim Lenograstim (genetical recombination) Lenograstim rDNA | |
| | 2 | | Thiotepa | approved | Phase 4, Phase 1 | 216 | 52-24-4 | 5453 | | | 3 | | Cyclophosphamide | approved, investigational | Phase 4, Phase 2, Phase 1 | 2829 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Anhydrous cyclophosphamide Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 | DB00531 DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide |
| | 4 | | Immunosuppressive Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 12770 | | | | 5 | | Alkylating Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 4694 | | | | 6 | | Antilymphocyte Serum | | Phase 4, Phase 2 | 399 | | | | 7 | | Antineoplastic Agents, Alkylating | | Phase 4, Phase 3, Phase 2, Phase 1 | 4474 | | | | 8 | | Antirheumatic Agents | | Phase 4, Phase 2, Phase 1 | 10627 | | | | 9 | | Cytarabine | approved, investigational | Phase 3, Phase 2, Phase 1 | 1093 | 147-94-4 | 6253 | (beta-D-Arabinofuranosyl)cytosine (beta-D-arabinofuranosyl)cytosine 1-.beta.-D-arabinofuranosyl-cytosine 1-Arabinofuranosylcytosine 1-beta -D-Arabinofaranosylcytosine 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone 1-beta -D-Arabinofuranosylcytosine 1-beta-D-Arabinofaranosylcytosine 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone 1-beta-D-Arabinofuranosyl-Cytosine 1-beta-D-Arabinofuranosylcytosine 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside 1-beta-D-Arabinosyl-Cytosine 1-beta-D-Arabinosylcytosine 147-94-4 1beta -Arabinofuranasylcytosine 1beta -D-Arabinofuranosylcytosine 1beta -D-Arabinosylcytosine 1beta-Arabinofuranasylcytosine 1beta-D-Arabinofuranosylcytosine 1beta-D-Arabinosylcytosine 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS] 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl 30399_FLUKA 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech] 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech] 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one 69-74-9 (hydrochloride) AC-1075 AC1L1M4F AC1Q52OJ AI3-52329 AR3 Alexan Ara-C Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine Ara-Cytidine AraC Arabinocytidine Arabinofuranosyl Cytidine Arabinofuranosylcytosine Arabinosyl Cytosine Arabinosylcytosine Arabitin Aracytidine Aracytin Aracytine Arafcyt BIDD:GT0371 BIDD:PXR0139 BTB15125 Beta-cytosine arabinoside C02961 C1768_SIGMA C2035 C9H13N3O5 CCRIS 913 CHEBI:28680 CHEMBL803 CHX 3311 CID6253 CPD000449317 CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9) Citarabina Citarabina [INN-Spanish] Cytarabin Cytarabina Cytarabine Cytarabine (JP15/USP/INN) | Cytarabine [USAN:INN:BAN:JAN] Cytarabine liposome injection Cytarabinoside Cytarabinum Cytarabinum [INN-Latin] Cytarbel Cytonal Cytosar Cytosar-U Cytosine 1-beta-D-arabinofuranoside Cytosine arabinofuranoside Cytosine arabinose Cytosine arabinoside Cytosine arabinoside (VAN) Cytosine beta-D-arabinofuranoside Cytosine beta-D-arabinofuranoside hydrochloride Cytosine beta-D-arabinoside Cytosine, beta -D-arabinoside Cytosine, beta-D-arabinoside Cytosine-1-beta-D-arabinofuranoside Cytosine-1-beta-D-arabinofuranoside hydrochloride Cytosine-beta -D-arabinofuranoside Cytosine-beta -arabinoside Cytosine-beta-D-arabinofuranoside Cytosine-beta-arabinoside Cytosinearabinoside D00168 DB00987 DepoCyte Depocyt Depocyt (TN) Depocyt (liposomal) Depocyte EINECS 205-705-9 Erpalfa FT-0082880 HMS2051K19 HMS2090A18 HSDB 3049 Intrathecal (injected into the spinal fluid) DepoCyt Intrathecal cytarabine (also known as ara-C) Iretin LS-860 Lopac0_000316 MLS000758310 MLS001066340 MolPort-001-792-509 NCGC00093356-03 NCGC00093356-04 NCGC00093356-05 NCI-C04728 NSC 287459 NSC287459 S1648_Selleck SAM001247012 SMR000449317 SR-01000075773-3 Spongocytidine TL8001048 Tarabine U 19920A U-19,920 U-19920 UNII-04079A1RDZ Udicil ZINC03795098 beta -D-arabinosylcytosine beta -arabinosylcytosine beta -cytosine arabinoside beta-Ara C beta-Ara c beta-Arabinosylcytosine beta-Cytosine arabinoside beta-D-Arabinosylcytosine cytarabine cytarabine liposome injection cytosine-β-D-arabinofuranoside |
| | 10 | | Arsenic trioxide | approved, investigational | Phase 2, Phase 3, Phase 1 | 119 | 1327-53-3 | 518740 | 28380-38-3 AC1L24QX AI3-01163 Acide Arsenieux Acide Arsenieux [French] Acide arsenieux [French] Anhydride Arsenieux Anhydride Arsenieux [French] Anhydride arsenieux [French] Arseneous anhydride Arseneous oxide Arseni Trioxydum Arseni trioxydum Arsenic Blanc Arsenic Blanc [French] Arsenic Oxide Arsenic Oxidearsenous Trioxide Arsenic Sesquioxide Arsenic Trioxide [UN1561] [Poison] Arsenic blanc [French] Arsenic oxide Arsenic oxide (As2O3) Arsenic sesquioxide Arsenic trioxide (JP15/USAN) Arsenic trioxide [JAN] Arsenic trioxide [UN1561] [Poison] Arsenic(III) oxide Arsenic(III) trioxide Arsenic, White Arsenicum Album Arsenicum album Arsenigen Saure Arsenigen Saure [German] Arsenigen saure [German] Arsenious Acid Arsenious Acid Anhydride Arsenious Oxide Arsenious Trioxide Arsenious trioxide Arsenite Arsenolite Arsenous Acid | Arsenous Acid Anhydride Arsenous Anhydride Arsenous Oxide Arsenous Oxide Anhydride Arsenous oxide [ISO] Arsenox Arsentrioxide Arsodent C006632 CCRIS 5455 CHEMBL405991 CID14888 Caswell No. 059 Claudelite Claudetite Crude Arsenic D02106 Di-Arsenic Trioxide Diarsenic Trioxide Diarsenic trioxide Diarsonic Trioxide EINECS 215-481-4 EPA Pesticide Chemical Code 007001 HSDB 419 LS-761 MolPort-006-823-587 Oxyde Arsenieux Oxyde Arsenieux [ISO-French] Poison Flour RCRA waste no. P012 Rcra waste number P012 Tetraarsenic hexaoxide Trisenox Trisenox (TN) Trixenox UN 1561 UN1561 UNII-S7V92P67HO White Arsenic White arsenic arsenic trioxide arsenic(3+) naonobin oxygen(2-) |
| | 11 | | Azacitidine | approved, investigational | Phase 2, Phase 3, Phase 1 | 506 | 320-67-2 | 9444 | 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one 320-67-2 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one 4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one 5 AZC 5 Azacytidine 5-AC 5-AZAC 5-AZCR 5-Azacytidine 5-aza-CR 5-azacitidine 5-azacytidine 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine 5AzaC A 2385 A1287_SIGMA A2385_SIGMA AC1L1T1Y Antibiotic U 18496 Azacitidina Azacitidina [INN-Spanish] Azacitidine Azacitidine (JAN/USAN/INN) Azacitidine [USAN:INN] Azacitidinum Azacitidinum [INN-Latin] Azacytidine BCBcMAP01_000083 BRN 0620461 BSPBio_003157 C11262 CCRIS 60 CHEBI:2038 CHEMBL1489 CID9444 CPD000857239 D001374 D03021 DB00928 DivK1c_000125 EINECS 206-280-2 EU-0100035 FT-0081170 HMS1921J22 HMS2092D08 HMS500G07 HSDB 6879 IDI1_000125 InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1 | Jsp005945 KBio1_000125 KBio2_001742 KBio2_002556 KBio2_004310 KBio2_005124 KBio2_006878 KBio2_007692 KBio3_002657 KBio3_003034 KBioGR_001444 KBioGR_002556 KBioSS_001742 KBioSS_002565 LS-1189 Ladakamycin Lopac0_000035 MLS001333121 MLS001333122 MLS002153249 MolMap_000062 Mylosar NCGC00090851-01 NCGC00090851-02 NCGC00090851-03 NCGC00090851-04 NCGC00090851-08 NCGC00178234-01 NCI-C01569 NINDS_000125 NS-17 NSC 102816 NSC-102816 NSC102816 Pharmion Brand of Azacitidine S1782_Selleck SAM002264595 SMR000857239 SPBio_000892 SPECTRUM1502111 ST056940 Spectrum2_000786 Spectrum3_001509 Spectrum4_000922 Spectrum5_001166 Spectrum_001262 TL80073599 U 18496 U-18496 UNII-M801H13NRU Vidaza Vidaza (TN) WR-183027 ZINC03861768 cMAP_000082 mylo sar pyrimidine antimetabolite: inhibits nucleic acid replication s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI) wr 183027 |
| | 12 | | alemtuzumab | approved, investigational | Phase 2, Phase 3 | 303 | 216503-57-0 | | | | 13 | | Etoposide | approved | Phase 3, Phase 2, Phase 1 | 1232 | 33419-42-0 | 36462 | (-)-Etoposide 121471-01-0 136598-18-0 201594-04-9 33419-42-0 35317-32-9 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside 51854-34-3 76576-58-4 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one AB00438905 AC1L1FN8 AC1L1VT3 AC1L6246 AC1NR4OG AC1O4WGG AC1O7M1N AC1Q47JJ Ambap33419-42-0 BPBio1_000673 BRD-K37798499-001-02-5 BSPBio_000611 Bio1_000489 Bio1_000978 Bio1_001467 C01576 CCRIS 2392 CHEBI:4911 CHEBI:588795 CHEMBL44657 CID11758093 CID284997 CID3310 CID36462 CID5284558 CID6419930 CID6610299 CPD000112002 D00125 DB00773 DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE, Demethyl Epipodophyllotoxin Ethylidine Glucoside Demethyl-epiodophyllotoxin ethylidene glucoside Demethylepipodophyllotoxin-beta-D-ethylideneglucoside E0675 E1383_SIGMA EINECS 251-509-1 EPE EPEG ETOP Epipodophyllotoxin Epipodophyllotoxin VP-16213 Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside) Eposide Eposin | Eposin, Vepesid, VP-16, Toposar, Etoposide Etopol Etopophos Etopophos (phosphate salt) Etoposid Etoposide Etoposide (JP15/USP/INN) Etoposide (VP16) Etoposide [USAN:INN:BAN:JAN] Etoposido Etoposido [INN-Spanish] Etoposidum Etoposidum [INN-Latin] Etosid HMS1569O13 HMS2052N05 HMS2089F14 HSDB 6517 I06-0248 KBioSS_002410 LS-1214 Lastet MLS000049957 MLS001074951 MLS001424283 MLS002153463 MLS002207239 MLS002222184 MolPort-003-983-431 MolPort-004-905-001 MolPort-004-955-161 NCGC00025056-02 NChemBio.2007.10-comp19 NK 171 NSC 141540 NSC-141540 NSC141540 Prestwick0_000396 Prestwick1_000396 Prestwick2_000396 Prestwick3_000396 Prestwick_211 S1225_Selleck SAM001246880 SMR000112002 SPBio_002532 ST056353 Toposar UNII-6PLQ3CP4P3 VP 16 VP 16 (pharmaceutical) VP 16-213 VP 16213 VP-16 VP-16-213 VePESID (TN) VePesid Vepesid Vepesid J Vepeside ZINC03830818 ZINC03938684 Zuyeyidal etoposide nchembio.573-comp8 nchembio873-comp2 trans-Etoposide |
| | 14 | | Fludarabine | approved | Phase 2, Phase 3, Phase 1 | 1113 | 21679-14-1, 75607-67-9 | 30751 | (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-F-ARAA 2-F-ara-A 2-Fluoro Ara-A 2-Fluoro-9-beta-D-arabinofuranosyladenine 2-fluoro ARA-A 21679-14-1 9-beta-D-Arabinofuranosyl-2-fluoroadenine 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI) AC1LCW8I AC1Q51CF C10H12FN5O4 CCRIS 3382 CHEMBL1568 CID657237 CPD000058874 D07966 EINECS 244-525-5 F-Ara-A FAMP FT-0082766 FaraA Fludara Fludara, Fludarabine | Fludarabina Fludarabina [Spanish] Fludarabine Fludarabine (INN) Fludarabine 5'-monophosphate Fludarabine [INN] Fludarabine monophosphate Fludarabine phosphate Fludarabinum Fludarabinum [Latin] Fludura Fluradosa Fluradosa (TN) HSDB 6964 I14-4978 LS-15061 MLS000028687 NSC 118218 NSC 118218H NSC-118218 S1491_Selleck SAM002548956 SMR000058874 SQ Fludarabine UNII-1X9VK9O1SC UNII-P2K93U8740 ZINC04216238 | |
| | 15 | | Busulfan | approved, investigational | Phase 3, Phase 2 | 540 | 55-98-1 | 2478 | 1, 4-Dimethanesulfonoxybutane 1, 4-Dimethylsulfonoxybutane 1, {4-Bis[methanesulfonoxy]butane} 1,4-BUTANEDIOL DIMETHANESULFONATE 1,4-Bis(methanesulfonoxy)butane 1,4-Bis(methanesulfonyloxy)butane 1,4-Bis[methanesulfonoxy]butane 1,4-Butanedi yl dimethanesulfonate 1,4-Butanediol dimethanesulfonate 1,4-Butanediol dimethanesulphonate 1,4-Butanediol dimethylsulfonate 1,4-Butanediol, dimethanesulfonate 1,4-Butanediol, dimethanesulphonate 1,4-Butanediyl dimethanesulfonate 1,4-Di(methylsulfonoxy)butane 1,4-Dimesyloxybutane 1,4-Dimethane sulfonyl oxybutane 1,4-Dimethanesulfonoxybutane 1,4-Dimethanesulfonoxylbutane 1,4-Dimethanesulfonyloxybutane 1,4-Dimethanesulphonyloxybutane 1,4-Dimethylsulfonoxybutane 1,4-Dimethylsulfonyloxybutane 2041 C. B 2041 C. B. 2041 C.B 2041 C.B. 4-((Methylsulfonyl)oxy)butyl methanesulfonate 4-methylsulfonyloxybutyl methanesulfonate 55-98-1 AC-198 AC1L1DRQ AC1Q4GRQ AI3-25012 AKOS003614975 AN 33501 Ambap55-98-1 B1022 B2635_FLUKA B2635_SIGMA BRN 1791786 BSPBio_001920 BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE) Bisulfex Busilvex Busulfan Busulfan (JP15/USP/INN) Busulfan GlaxoSmithKline Brand Busulfan Orphan Brand Busulfan Wellcome Busulfan Wellcome Brand Busulfan [INN:JAN] Busulfano Busulfano [INN-Spanish] Busulfanum Busulfanum [INN-Latin] Busulfex Busulphan Busulphane Butanedioldimethanesulfonate Buzulfan C.B. 2041 C6H14O6S2 CB 2041 CCRIS 418 CHEBI:28901 CHEMBL820 CID2478 CPD000058613 Citosulfan D002066 D00248 DB01008 DivK1c_000847 EINECS 200-250-2 FT-0083567 G.T. 41 GT 2041 GT 41 Glaxo Wellcome Brand of Busulfan GlaxoSmithKline Brand of Busulfan Glyzophrol HMS1920I07 HMS2091O09 HMS502K09 | HSDB 7605 I09-1371 IDI1_000847 InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3 KBio1_000847 KBio2_000512 KBio2_003080 KBio2_005648 KBio3_001420 KBioGR_000698 KBioSS_000512 LS-1358 Leucosulfan MLS001076666 MYLERAN (TN) Mablin Methanesulfonic Methanesulfonic acid, tetram ethylene ester Methanesulfonic acid, tetramethylene ester Mielevcin Mielosan Mielucin Milecitan Mileran Misulban Mitosan Mitostan MolPort-001-783-406 Myeleukon Myeloleukon Myelosan Myelosanum Mylecytan Myleran Myleran Tablets Myleran tablets Myleran, Busulfex, Busulfan Mylerlan NCGC00090905-01 NCGC00090905-02 NCGC00090905-03 NCGC00090905-04 NCGC00090905-05 NCGC00090905-06 NCGC00090905-07 NCI-C01592 NCI60_041640 NCIMech_000192 NINDS_000847 NSC 750 NSC-750 NSC-750sulphabutin NSC750 Orphan Brand of Busulfan Prestwick_989 S1692_Selleck SAM002554887 SMR000058613 SPBio_000253 SPECTRUM1500152 ST50825921 Spectrum2_000067 Spectrum3_000320 Spectrum4_000259 Spectrum5_000928 Spectrum_000092 Sulfabutin Sulfabutin (VAN) Sulphabutin Tetramethylene Dimethane Sulfonate Tetramethylene bis(methanesulfonate) Tetramethylene bis[methanesulfonate] Tetramethylene dimethane sulfonate Tetramethylene {bis[methanesulfonate]} Tetramethylenester Kyseliny Methansulfonove Tetramethylenester kyseliny methansulfonove Tetramethylenester kyseliny methansulfonove [Czech] UNII-G1LN9045DK WLN: WS1&O4OSW1 Wellcome Brand of Busulfan Wellcome, Busulfan X 149 acid, tetramethylene ester alkylating agent: crosslinks guanine residues busulfan butane-1,4-diyl dimethanesulfonate n-Butane-1,3-di(methylsulfonate) |
| | 16 | | Mitoxantrone | approved, investigational | Phase 3, Phase 2, Phase 1 | 266 | 65271-80-9 | 4212 | 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE 1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione 137635-96-2 2fum 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone 65271-80-9 70476-82-3 70476-82-3 (hydrochloride) 70711-41-0 70711-41-0 (acetate) 70945-62-9 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI) AB00053716 AC1L1HNY AN-584/42007670 BIDD:PXR0181 BPBio1_000627 BRD-K21680192-300-05-2 BRD-K21680192-300-07-8 BRN 2795126 BSPBio_000569 BSPBio_003160 C11195 C22H28N4O6 CAS-70476-82-3 CCRIS 7604 CHEBI:50729 CHEMBL58 CID4212 D08224 DB01204 DHAD DHAQ DHAQ (*Diacetate salt*) DHAQ HCl Dihydroxyanthraquinone DivK1c_000516 HMS2090D05 IDI1_000516 KBio1_000516 KBio2_002135 KBio2_004703 KBio2_007271 KBio3_002660 KBioGR_001531 KBioSS_002135 LS-20638 Liposome Encapsulated Mitoxantrone (LEM) Lopac-M-6545 Lopac0_000779 MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE MIX | MLS002703044 Misostol Misostol (TN) Mitox Mitoxanthrone Mitoxantron Mitoxantrona Mitoxantrona [INN-Spanish] Mitoxantrone Mitoxantrone (INN) Mitoxantrone (free base) Mitoxantrone 2HCl Mitoxantrone HCl Mitoxantrone [INN] Mitoxantrone dihydrochloride Mitoxantrone hydrochloride Mitoxantronum Mitoxantronum [INN-Latin] Mitozantrone Mitozantrone hydrochloride MolPort-003-849-239 NCGC00015693-01 NCGC00015693-02 NCGC00015693-04 NCGC00162251-01 NCI60_002276 NCI60_002535 NChemBio.2007.10-comp17 NINDS_000516 NSC 279836 NSC-279836 NSC-287836 NSC-299195 NSC-301739 NSC-301739D NSC279836 NSC299195 NSC301739 Neuro_000153 Novantron Novantrone Novantrone(R) (mitoxantrone for injection concentrate) Prestwick0_000385 Prestwick1_000385 Prestwick2_000385 Prestwick3_000385 S2485_Selleck SMP2_000179 SMR001549953 SPBio_000756 SPBio_002490 SR-01000076001 SR-01000076001-7 STK631833 Spectrum2_000908 Spectrum3_001590 Spectrum4_000866 Spectrum5_001205 Spectrum_001655 UNII-BZ114NVM5P VU0244399-2 mitoxantrone |
| | 17 | | Melphalan | approved | Phase 2, Phase 3 | 712 | 148-82-3 | 4053, 460612 | (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid 148-82-3 3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine 3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3025 C.B. 3025 c.b 3223-07-2 4-(Bis(2-chloroethyl)amino)-L-phenylalanine 4-14-00-01689 (Beilstein Handbook Reference) 4-[Bis(2-chloroethyl)amino]-L-phenylalanine 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine AC1LA2OE ALKERAN (TN) AY3360000 Alanine Nitrogen Mustard Alkeran AmbotzHAA1563 At-290 BIDD:GT0044 BRD-K87827419-001-02-8 BRN 2816456 BSPBio_002407 C13H18Cl2N2O2 CB 3025 CB-3025 CCRIS 374 CHEBI:165415 CHEBI:28876 CHEMBL852 CID460612 D00369 DivK1c_000653 EINECS 205-726-3 HMS2090B09 HMS2091B16 HMS502A15 HSDB 3234 IDI1_000653 KBio1_000653 KBio2_000877 KBio2_003445 KBio2_006013 KBio3_001627 KBioGR_001284 KBioSS_000877 L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine L-PAM L-Phenylalanine mustard L-Sarcolysin L-Sarcolysine L-Sarkolysin LS-15868 LS-865 | Levofalan Levofolan Levopholan M2011_SIGMA MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)) MLS001333666 MLS002153368 Melfalan Melfalano Melfalano [INN-Spanish] Melphalan (JP15/USP/INN) Melphalan [USAN:INN:BAN:JAN] Melphalanum Melphalanum [INN-Latin] Mephalan MolPort-003-665-535 NCGC00090757-01 NCGC00090757-02 NCGC00090757-03 NCI-C04853 NINDS_000653 NIOSH/AY3360000 NSC 241286 NSC 8806 NSC-8806 NSC241286 NSC8806 P-Di-(2-chloroethyl)amino-L-phenylalanine P-L-Sarcolysin P-N-Bis(2-chloroethyl)amino-L-phenylalanine Phenylalanine mustard Phenylalanine nitrogen mustard Prestwick_1006 RCRA waste no. U150 Rcra waste number U150 SK-15673 SMP2_000174 SMR000058720 SPBio_000287 SPECTRUM1500382 Sarcolysine Sarkolysin Spectrum2_000074 Spectrum3_000684 Spectrum4_000882 Spectrum5_001601 Spectrum_000397 TL8001065 TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN) TRANSGENIC MODEL EVALUATION (MELPHALAN) UNII-Q41OR9510P melphalan p-Bis(beta-chloroethyl)aminophenylalanine p-Di-(2-chloroethyl)amino-L-phenylalanine p-L-Sarcolysin p-L-sarcolysine p-N,N-bis(2-chloroethyl)amino-L-phenylalanine p-N-Bis(2-chloroethyl)amino-L-phenylalanine p-N-Di(chloroethyl)aminophenylalanine p-N-di(chloroethyl)aminophenylala nine phenylalanine nitrogen mu stard |
| | 18 | | Clofarabine | approved, investigational | Phase 2, Phase 3, Phase 1 | 157 | 123318-82-1 | 119182 | (2R,3R,4S,5R)-5-(6-amino-2-Chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol 123318-82-1 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine 2-Cl-2'-F-araA 2-chloro-9-(2'-Deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine 2-chloro-9-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine 3S211048 AC-274 AC1L3OC8 AKOS005063562 Bio-0121 C1-F-Ara-A CAFdA CFB CHEBI:681569 CHEMBL1750 CID119182 CL-F-Ara-a | Cl-F-Ara-A Clofarabin Clofarabina Clofarabine Clofarabine (USAN/INN) Clofarabine [USAN] Clofarabinum Clofarex Clolar Clolar (TN) Clolar, Evoltra, Clofarabine D03546 DB00631 DB07554 Evoltra FT-0082882 HMS2090A07 LS-126466 MolPort-005-941-711 S1218_Selleck UNII-762RDY0Y2H ZINC03798247 clofarabina clofarabinum |
| | 19 | | Daunorubicin | approved | Phase 3, Phase 2, Phase 1 | 264 | 20830-81-3 | 30323 | (+)-Daunomycin (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione 11006-54-5 11048-29-6 1407-15-4 149541-57-1 20830-81-3 23942-76-9 27576-81-4 28020-80-6 AB00514669 AC1L1JCP AC1Q29OI AI3-52942 Acetyladriamycin Anthracyline Antibiotics From Streptomyces Coeruleorubidus Antibiotics from Streptomyces coeruleorubidus BPBio1_000389 BRD-K43389675-003-02-7 BRN 1445583 BSPBio_000353 C01907 CCRIS 914 CHEBI:41977 CHEMBL178 CID30323 Cerubidin Cerubidine D07776 DAUNORUBICIN HCL DB00694 DM1 Daunamycin Daunarubicinum Dauno-Rubidomycine DaunoXome DaunoXome (TN) Daunoblastin Daunoblastine Daunomycin | Daunomycin Hydrochloride Daunomycin, Hydrochloride Daunorrubicina Daunorubicin Daunorubicin (INN) Daunorubicin (liposomal) Daunorubicin Hcl Daunorubicin Hydrochloride Daunorubicin [INN:BAN] Daunorubicin, Hydrochloride Daunorubicina Daunorubicine Daunorubicinum Daunorubicinum [INN-Latin] Daunoxome EINECS 244-069-7 FI 6339 FI6339 HMS2089H04 HMS2091K06 HSDB 5095 LMPK13050002 LS-187381 LS-997 Leukaemomycin C MolPort-002-533-961 NCGC00024246-05 NCGC00024246-06 NCGC00025173-01 NCI-C04693 NChemBio.2007.10-comp14 NSC 83142 NSC-82151 Ondena Prestwick3_000487 RCRA waste no. U059 RP 13057 Rcra Waste No. U059 Rp 13057 Hydrochloride Rubidomycin Rubidomycin Hydrochloride Rubomycin Rubomycin C Tocris-1467 UNII-ZS7284E0ZP VS-103 daunorubicin nchembio723-comp2 |
| | 20 | | Aldesleukin | approved | Phase 3, Phase 2 | 397 | 85898-30-2, 110942-02-4 | | 125-L-serine-2-133-interleukin 2 (human reduced) | Interleukin-2 aldesleukin Interleukin-2(2-133),125-ser Recombinant interleukin-2 human |
| | 21 | | Thioguanine | approved | Phase 3 | 82 | 154-42-7 | 2723601 | 154-42-7 2 Amino 6 Purinethiol 2-Amino 6MP 2-Amino 6mp 2-Amino-1,7-dihydro-6H-purin-6-thion 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech] 2-Amino-1,7-dihydro-6H-purine-6-thione 2-Amino-6-MP 2-Amino-6-mercaptopurine 2-Amino-6-merkaptopurin 2-Amino-6-merkaptopurin [Czech] 2-Amino-6-purinethiol 2-Amino-9H-purine-6-thiol 2-Aminopurin-6-thiol 2-Aminopurin-6-thiol [Czech] 2-Aminopurine-6(1H)-thione 2-Aminopurine-6-thiol 2-Thioguanine 2-amino-1,9-Dihydropurine-6-thione 2-amino-1H-purine-6(7H)-thione 2-amino-3,7-dihydropurine-6-thione 2-aminopurine-6-thiol 5580-03-0 6 Thioguanine 6-Mercapto-2-aminopurine 6-Mercaptoguanine 6-TG 6-Thioguanine 6-Thioguanine (6-TG) 6-Thioguanine, Thioguanine A4660_SIGMA A4882_SIGMA AC-11125 AC1MC379 AI3-26078 AKOS003389499 BSPBio_001994 BW 5071 C07648 C5H7N5S CCRIS 8997 CHEBI:136864 CHEMBL727 CID2723601 D013866 D08603 DB00352 DX4 DivK1c_000428 EINECS 205-827-2 FT-0083572 Glaxo Wellcome Brand of Thioguanine Glaxo Wellcome Brand of Tioguanine GlaxoSmithKline Brand of Thioguanine GlaxoSmithKline Brand of Tioguanine Guanine, thio- (VAN) HMS1921E09 HMS2092M11 HMS501F10 HSDB 2504 I14-1541 IDI1_000428 KBio1_000428 KBio2_000715 KBio2_002476 KBio2_003283 KBio2_005044 | KBio2_005851 KBio2_007612 KBio3_001494 KBio3_002954 KBioGR_001452 KBioGR_002476 KBioSS_000715 KBioSS_002483 LS-888 LT00455187 Lanvis Lanvis (TN) MLS001333131 MLS001333132 MolPort-000-929-106 MolPort-001-813-204 MolPort-003-984-174 NCGC00094792-01 NCGC00094792-02 NCGC00094792-03 NCI60_041643 NCIOpen2_004153 NINDS_000428 NSC 752 NSC-752 NSC752 S1774_Selleck SBB067147 SMP2_000326 SMR000857244 SPBio_000849 SPECTRUM1500573 ST50298831 Spectrum2_000695 Spectrum3_000577 Spectrum4_000926 Spectrum5_001455 Spectrum_000235 T0212 TG THG Tabloid ThG Thioguanin GSK Thioguanin-GSK ThioguaninGSK Thioguanine Thioguanine Hemihydrate Thioguanine Monosodium Salt Thioguanine Tabloid Thioguanine [USAN:BAN] Tioguanin Tioguanina Tioguanina Wellcome Tioguanina [INN-Spanish] Tioguanine Tioguanine (INN) Tioguanine GlaxoSmithKline Brand Tioguaninum Tioguaninum [INN-Latin] UNII-FTK8U1GZNX UNII-WIX31ZPX66 WLN: T56 BNM FYM INJ FUS HZ Wellcome Brand of Thioguanine Wellcome U3B ZINC18085533 cMAP_000061 purine antimetabolite: antimetabolite: inhibits nucleic acid replication thioguanine |
| | 22 | | Dexamethasone | approved, investigational, vet_approved | Phase 3, Phase 1 | 2084 | 50-02-2 | 5743 | (3H)-Dexamethasone .delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol .gamma.corten 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone 1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone 1-Dehydro-16α-methyl-9α-fluorohydrocortisone 137098-19-2 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone 16-alpha-Methyl-9-alpha-fluoroprednisolone 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol 16.alpha.-Methyl-9.alpha.-fluoroprednisolone 16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol 16alpha -Methyl-9alpha -fluoroprednisolone 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone 16alpha-Methyl-9alpha-fluoroprednisolone 16α-Methyl-9α-fluoro-1-dehydrocortisol 23495-06-9 31375_FLUKA 46165_FLUKA 46165_RIEDEL 50-02-2 8054-59-9 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione 9-Fluoro-16-methylprednisolone 9-alpha-Fluoro-16-alpha-methylprednisolone 9.alpha.-Fluoro-16.alpha.-methylprednisolone 906422-84-2 9A-FLUORO-16BETA-METHYLPREDNISOLONE 9alpha -Fluoro-16alpha -methylprednisolone 9alpha-Fluoro-16alpha-methylprednisolone 9alpha-fluoro-16alpha-methyl-Prednisolone 9α-Fluoro-16α-methylprednisolone AC-11056 AC1L1L1H AC1Q29DM AI3-50934 Adexone Aeroseb-D Aeroseb-Dex Aeroseb-dex Ak Dex Oph Otic Soln 0.1% Alcon Brand of Dexamethasone Anaflogistico Aphtasolon Aphthasolone Apo-dexamethasone Auxiron Azimycin (veterinary) Azium Azium (Veterinary) Azium (veterinary) BIDD:ER0494 BIDD:PXR0060 BRD-K38775274-001-02-3 BRD-K38775274-001-06-4 BSPBio_000995 Bisu DS Bisu Ds C15643 C22H29FO5 CCRIS 7067 CHEBI:41879 CHEMBL384467 CID5743 CPD-10549 CPD001227192 Calonat Corson Corsone Cortisumman D00292 D003907 D1756_SIGMA D4902_SIGMA D6645_SIGMA D8893_SIGMA D9184_SIGMA DB01234 DEX DEXA DEXONE 0.5 DEXONE 0.75 DEXONE 1.5 DEXONE 4 DXM DXMS Decacort Decacortin Decaderm Decadron Decadron (TN) Decadron Tablets, Elixir Decadron, Dexamethasone Decadron-LA Decadron-La Decagel Decaject Decaject L.A. Decaject-L.A. Decalix Decameth Decasone Decaspray Dectancyl Dekacort Delta1-9alpha-Fluoro-16alpha-methylcortisol Deltafluorene Dergramin Deronil Desadrene Desametasone Desametasone [DCIT] Desametasone [Dcit] Desamethasone Desameton Deseronil Dex-Ide Dex-ide Dexa Dexa Mamallet Dexa mamallet Dexa-Cortidelt Dexa-Cortisyl Dexa-Mamallet Dexa-Scheroson Dexa-Sine Dexa-cortidelt Dexa-cortisyl Dexa-scheroson Dexa-sine Dexacen-4 Dexacidin Dexacort Dexacortal Dexacortin Dexadeltone Dexafarma Dexair Dexalona Dexaltin Dexametasona Dexametasona [INN-Spanish] Dexametasone | Dexameth Dexamethansone Dexamethasone Dexamethasone (JP15/USP/INN) Dexamethasone Acetate Dexamethasone Alcohol Dexamethasone Base Dexamethasone Intensol Dexamethasone Sodium Phosphate Dexamethasone [INN:BAN:JAN] Dexamethasone alcohol Dexamethasone base Dexamethasone intensol Dexamethasone-omega Dexamethasonum Dexamethasonum [INN-Latin] Dexamethazone Dexamonozon Dexapolcort Dexapos Dexaprol Dexason Dexasone Dexasone 0.5mg Dexasone 0.75mg Dexasone 4mg Dexasporin Dexinolon Dexinoral Dexone Dexone 0.5 Dexone 0.75 Dexone 1.5 Dexone 4 Dexonium Dexpak Dextelan Dezone Dinormon Dxms ECR Brand of Dexamethasone EINECS 200-003-9 FT-0080377 Fluormethylprednisolone Fluormone Fluorocort Fortecortin Foy Brand of Dexamethasone Gammacorten HL-dex HMS1792A17 HMS1990A17 HMS2089N13 HSDB 3053 Hexadecadrol Hexadrol Hexadrol Elixir Hexadrol Tablets Hexadrol elixir Hl-Dex Hl-dex I06-1196 ICN Brand of Dexamethasone IontoDex Isopto-Dex Isopto-dex LS-7300 Lokalison F Lokalison f Loverine Luxazone MK 125 MLS001055412 MLS001332507 MLS001332508 Maxidex Maxidex Ont 0.1% Maxidex Sus 0.1% Maxitrol Mediamethasone Merck Brand of Dexamethasone Merz Brand 1 of Dexamethasone Merz Brand 2 of Dexamethasone Methylfluorprednisolone Mexidex Millicorten MolMap_000018 MolPort-003-846-433 Mymethasone NCGC00091019-01 NCGC00091019-02 NCGC00091019-03 NCGC00091019-04 NCGC00091019-05 NCI60_003067 NSC 34521 NSC34521 Naquasone (veterinary) Neomycin and polymyxin b sulfates and dexamethasone Neomycin and polymyxin b sulphates and dexamethasone OTO-104 Ocu-Trol Ocu-trol Oradexon PHL-dexamethasone PMS-dexamethasone Pet Derm III Pet Derm Iii Pet derm III Pet-Derm Iii Pms Dexamethasone Elixir 0.5mg/5ml Policort Posurdex Prednisolon F Prednisolon f Prednisolone F Prednisolone f Prodex S1322_Selleck SAM002548948 SGCUT00126 SK-Dexamethasone SK-dexamethasone SMP1_000092 SMR000857119 SMR001227192 ST50307091 Sandoz dexamethasone Sk-Dexamethasone Spectrum5_002019 Spoloven Sunia Sol D Sunia sol D Superprednol TL8003317 Tobradex Tobramycin and dexamethasone Tresaderm (veterinary) Turbinaire UNII-7S5I7G3JQL Visumetazone WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1 ZINC03875332 alpha -Fluoro-16-alpha -methylcortisol delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol delta1-9alpha-Fluoro-16alpha-methylcortisol dexamethasone nchembio809-comp2 to_000038 |
| | 23 | | Asparaginase | approved | Phase 3 | 222 | 9015-68-3 | | | Elspar L-asparagine amidohydrolase Putative L-asparaginase precursor |
| | 24 | | tipifarnib | investigational | Phase 2, Phase 3, Phase 1 | 82 | 192185-72-1 | 159324 | (R)-( )-R115777 (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 192185-72-1 1x81 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H )-quinolinone 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE AC1L4LN0 AC1Q3OVC AR-1H0635 AR-1H0636 CCRIS 9329 CHEMBL289228 CID159324 D03720 | IND58359 JAN LS-184411 LS-187005 LS-187640 NSC-702818 R 115777 R-11577 R-115777 R115777 S1453_Selleck Tipifarnib Tipifarnib (USAN/INN) Tipifarnib [USAN] UNII-MAT637500A Zarnestra Zarnestra, IND 58359, R115777, Tipifarnib tipifarnib |
| | 25 | | Staurosporine | experimental | Phase 3 | 45 | 62996-74-1 | | | 26 | | Antibiotics, Antitubercular | | Phase 3, Phase 2, Phase 1 | 6972 | | | | 27 | | Anti-Bacterial Agents | | Phase 3, Phase 2, Phase 1 | 10884 | | | | 28 | | Antiviral Agents | | Phase 3, Phase 2, Phase 1 | 9732 | | | | 29 | | Antimetabolites, Antineoplastic | | Phase 3, Phase 2, Phase 1 | 7171 | | | | 30 | | Anti-Infective Agents | | Phase 3, Phase 2, Phase 1 | 21402 | | | | 31 | | Antimetabolites | | Phase 3, Phase 2, Phase 1 | 11774 | | | | 32 | | Gemtuzumab | | Phase 2, Phase 3 | 71 | | | | 33 | | Topoisomerase Inhibitors | | Phase 3, Phase 2, Phase 1 | 4945 | | | | 34 | | Protein Kinase Inhibitors | | Phase 3, Phase 2, Phase 1 | 3612 | | | | 35 | | Analgesics, Non-Narcotic | | Phase 3 | 6260 | | | | 36 | | Etoposide phosphate | | Phase 3, Phase 2, Phase 1 | 1232 | | | | 37 | | Analgesics | | Phase 3, Phase 2, Phase 1 | 11287 | | | | 38 | | Antineoplastic Agents, Phytogenic | | Phase 3, Phase 2, Phase 1 | 5420 | | | | 39 | | Interleukin-2 | | Phase 3 | 553 | | | | 40 | | Peripheral Nervous System Agents | | Phase 3, Phase 2, Phase 1 | 22776 | | | | 41 | | Anti-Retroviral Agents | | Phase 3, Phase 2 | 3232 | | | | 42 | | Anti-HIV Agents | | Phase 3, Phase 2 | 3100 | | | | 43 | | HIV Protease Inhibitors | | Phase 3, Phase 1 | 5319 | | | | 44 | | glucocorticoids | | Phase 3, Phase 1 | 4920 | | | | 45 | | protease inhibitors | | Phase 3, Phase 1 | 5320 | | | | | 46 | | Gastrointestinal Agents | | Phase 3, Phase 1 | 8109 | | | | 47 | | Hormones | | Phase 3, Phase 1 | 13979 | | | | 48 | | Hormone Antagonists | | Phase 3, Phase 1 | 12778 | | | | 49 | | Hormones, Hormone Substitutes, and Hormone Antagonists | | Phase 3, Phase 1 | 12767 | | | | 50 | | Anti-Inflammatory Agents | | Phase 3, Phase 1 | 10355 | | |
Interventional clinical trials: (show top 50)
(show all 62)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | Completed | NCT00003398 | Phase 4 | | 2 | Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | Unknown status | NCT00091234 | Phase 2, Phase 3 | | 3 | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | Completed | NCT00006363 | Phase 3 | | 4 | S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML | Completed | NCT00085709 | Phase 3 | | 5 | Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia | Completed | NCT00112554 | Phase 3 | | 6 | Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | Completed | NCT00454480 | Phase 2, Phase 3 | | 7 | Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes | Active, not recruiting | NCT00369317 | Phase 3 | | 8 | Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | NCT00372593 | Phase 3 | | 9 | Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | NCT00651261 | Phase 3 | | 10 | Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia | Unknown status | NCT00003758 | Phase 2 | | 11 | VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia | Unknown status | NCT00354276 | Phase 2 | | 12 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Completed | NCT00407966 | Phase 2 | | 13 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia | Completed | NCT00352365 | Phase 2 | | 14 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | Completed | NCT00096122 | Phase 1, Phase 2 | | 15 | Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | Completed | NCT00027872 | Phase 2 | | 16 | Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | Completed | NCT00666588 | Phase 2 | | 17 | Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | Completed | NCT00003396 | Phase 2 | | 18 | Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | NCT00775593 | Phase 2 | | 19 | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | Completed | NCT01235572 | Phase 2 | | 20 | S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | Completed | NCT00023777 | Phase 2 | | 21 | Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia | Completed | NCT00089050 | Phase 2 | | 22 | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | Recruiting | NCT02071901 | Phase 2 | | 23 | Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | Active, not recruiting | NCT01627041 | Phase 2 | | 24 | Busulfan, Etoposide, and Total-Body Irradiation Followed by Autologous Stem Cell Transplant and Aldesleukin in Treating Patients With Acute Myeloid Leukemia in First Remission | Active, not recruiting | NCT00534469 | Phase 2 | | 25 | Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy | Active, not recruiting | NCT00509093 | Phase 2 | | 26 | A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia | Active, not recruiting | NCT01656031 | Phase 2 | | 27 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Terminated | NCT00096148 | Phase 2 | | 28 | Cilengitide in Treating Patients With Acute Myeloid Leukemia | Terminated | NCT00089388 | Phase 2 | | 29 | Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | Completed | NCT00131989 | Phase 1 | | 30 | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia | Completed | NCT00217646 | Phase 1 | | 31 | Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | Completed | NCT00383474 | Phase 1 | | 32 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | Completed | NCT00098423 | Phase 1 | | 33 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | Completed | NCT00357305 | Phase 1 | | 34 | XK469R in Treating Patients With Refractory Hematologic Cancer | Completed | NCT00095797 | Phase 1 | | 35 | Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders | Completed | NCT00293410 | Phase 1 | | 36 | Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | Completed | NCT00005092 | Phase 1 | | 37 | Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | Completed | NCT00093483 | Phase 1 | | 38 | Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | Completed | NCT00101153 | Phase 1 | | 39 | Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia | Completed | NCT00258271 | Phase 1 | | 40 | 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome | Completed | NCT00077558 | Phase 1 | | 41 | Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders | Completed | NCT00114257 | Phase 1 | | 42 | Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer | Completed | NCT00003395 | Phase 1 | | 43 | Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy | Completed | NCT00030108 | Phase 1 | | 44 | A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status | Completed | NCT00462761 | Phase 1 | | 45 | Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | NCT01154439 | Phase 1 | | 46 | Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | Active, not recruiting | NCT00295841 | Phase 1 | | 47 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia | Terminated | NCT01550185 | Phase 1 | | 48 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | Terminated | NCT00101231 | Phase 1 | | 49 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | Terminated | NCT01260714 | Phase 1 | | 50 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | Terminated | NCT01159301 | Phase 1 |
Inferred drug relations via UMLS68/NDF-RT46:
|
